HK1217759A1 - 檢測血清樣品中抗藥物抗體的干擾抑制性免疫測定 - Google Patents

檢測血清樣品中抗藥物抗體的干擾抑制性免疫測定

Info

Publication number
HK1217759A1
HK1217759A1 HK16105571.8A HK16105571A HK1217759A1 HK 1217759 A1 HK1217759 A1 HK 1217759A1 HK 16105571 A HK16105571 A HK 16105571A HK 1217759 A1 HK1217759 A1 HK 1217759A1
Authority
HK
Hong Kong
Prior art keywords
immunoassay
suppressed
interference
serum samples
drug antibodies
Prior art date
Application number
HK16105571.8A
Other languages
English (en)
Inventor
Kay-Gunnar Stubenrauch
Rudolf Vogel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1217759A1 publication Critical patent/HK1217759A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
HK16105571.8A 2013-07-04 2016-05-16 檢測血清樣品中抗藥物抗體的干擾抑制性免疫測定 HK1217759A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13175091 2013-07-04
PCT/EP2014/063891 WO2015000865A1 (en) 2013-07-04 2014-07-01 Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples

Publications (1)

Publication Number Publication Date
HK1217759A1 true HK1217759A1 (zh) 2017-01-20

Family

ID=48703341

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16105571.8A HK1217759A1 (zh) 2013-07-04 2016-05-16 檢測血清樣品中抗藥物抗體的干擾抑制性免疫測定

Country Status (11)

Country Link
US (2) US10168326B2 (zh)
EP (1) EP3017303B1 (zh)
JP (2) JP6563910B2 (zh)
KR (1) KR102248581B1 (zh)
CN (1) CN105378480B (zh)
BR (1) BR112015032960B1 (zh)
CA (1) CA2913687C (zh)
HK (1) HK1217759A1 (zh)
MX (1) MX363403B (zh)
RU (1) RU2674996C2 (zh)
WO (1) WO2015000865A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
DK2493922T3 (en) 2009-10-26 2017-04-24 Hoffmann La Roche Process for preparing a glycosylated immunoglobulin
CN103476793A (zh) 2010-11-08 2013-12-25 基因技术公司 皮下施用的抗-il-6受体抗体
MX2016010413A (es) * 2014-02-11 2016-11-30 Genzyme Corp Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco.
WO2017102786A1 (en) * 2015-12-16 2017-06-22 F. Hoffmann-La Roche Ag Three-step acid dissociation enzyme linked immunosorbent (tadelis) assay
WO2018162475A1 (en) * 2017-03-07 2018-09-13 Roche Diagnostics Gmbh Stable formulations for immune-modulatory macrolides
CN110997727A (zh) * 2017-08-08 2020-04-10 豪夫迈·罗氏有限公司 用于确定微型猪样品中抗药物抗体的方法
JP7161534B2 (ja) * 2017-11-29 2022-10-26 エフ．ホフマン－ラ ロシュ アーゲー 標的による干渉が抑制された抗薬物抗体アッセイ
EP3821255A1 (en) * 2018-07-10 2021-05-19 Regeneron Pharmaceuticals, Inc. Methods for mitigating drug target interference in an anti-drug antibody (ada) immunoassay
CN113495141A (zh) * 2020-03-20 2021-10-12 迈克生物股份有限公司 2019新型冠状病毒IgM抗体检测试剂盒
JP2023526294A (ja) * 2020-05-18 2023-06-21 ビオシオン インコーポレイテッド Ｉｌ６ｒに結合する抗体及びその使用
KR102626197B1 (ko) * 2020-11-19 2024-01-18 바디텍메드(주) 항 약물 항체의 수준을 정확하게 정량화하는 방법
JP7062803B1 (ja) 2021-03-31 2022-05-06 積水メディカル株式会社 抗薬物抗体測定方法
CN114047343B (zh) * 2022-01-13 2022-05-31 美迪西普亚医药科技(上海)有限公司 双耐受型抗IgE单抗药物的免疫原性分析试剂盒及其使用方法和应用

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
JPH066054B2 (ja) 1987-10-15 1994-01-26 帝人株式会社 動物細胞の培養方法
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US6428979B1 (en) 1988-01-22 2002-08-06 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
CA1341152C (en) 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2
KR0143993B1 (ko) 1988-11-03 1998-07-15 리차아드 제이 매씨이 전기화학 발광성 분석
US5068088A (en) 1988-11-03 1991-11-26 Igen, Inc. Method and apparatus for conducting electrochemiluminescent measurements
KR0132666B1 (en) 1989-03-14 1998-04-14 Hitachi Kk Method for controlling cultivation conditions for animal cells
SG42954A1 (en) 1989-07-20 1997-10-17 Tadamitsu Kishimoto Antibody to human interleukin-6 receptor
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
IL100866A (en) 1991-02-06 1995-10-31 Igen Inc Luminescence test method and device based on magnetic tiny particles, containing many magnets
WO1992019759A1 (en) 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5821121A (en) 1991-06-24 1998-10-13 Pacific Biomedical Research, Inc. Hormone-secreting cells maintained in long-term culture
DE69311873T2 (de) 1992-05-01 1998-02-12 Teijin Ltd Fed-batch-Verfahren für Proteine sekretierende Zellen
EP0567738A3 (en) 1992-05-01 1995-09-06 American Cyanamid Co Controlling perfusion rates in continuous bioreactor culture of animal cells
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
JPH07258252A (ja) 1994-03-16 1995-10-09 Meiji Seika Kaisha Ltd チアゾール化合物およびその塩
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
JP3630453B2 (ja) 1994-09-30 2005-03-16 中外製薬株式会社 Ｉｌ−６レセプター抗体を有効成分とする未熟型骨髄腫細胞治療剤
EP0791359A4 (en) 1994-10-21 2002-09-11 Chugai Pharmaceutical Co Ltd MEDICINE AGAINST IL-6 PRODUCTION IN DISEASES
KR100252743B1 (ko) 1994-12-29 2000-09-01 나가야마 오사무 Il-6 안타고니스트를 함유하는 항종양제의 작용증강제
ES2264135T3 (es) 1995-02-13 2006-12-16 Chugai Seiyaku Kabushiki Kaisha Inhibidor de la descomposicion de proteinas musculares que contienen anticuerpos frente al receptor de il-6.
US5614191A (en) 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
AU718899C (en) 1995-10-23 2004-01-29 Amrad Operations Pty. Limited A novel haemopoietin receptor and genetic sequences encoding same
US6087129A (en) 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
EP0923941B1 (en) 1996-06-27 2006-05-17 Chugai Seiyaku Kabushiki Kaisha Remedies for myeloma to be used together with nitrogen mustard antitumor agents
WO1998041611A1 (en) 1997-03-20 1998-09-24 Regents Of The University Of Minnesota Process for the continuous culture of cells
ES2312184T3 (es) 1997-03-21 2009-02-16 Chugai Seiyaku Kabushiki Kaisha Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
CN100374159C (zh) 1998-03-17 2008-03-12 中外制药株式会社 一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂
US6537782B1 (en) 1998-06-01 2003-03-25 Chugai Seiyaku Kabushiki Kaisha Media for culturing animal cells and process for producing protein by using the same
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
ES2276525T3 (es) 1998-08-24 2007-06-16 Chugai Seiyaku Kabushiki Kaisha Preventivos o remedios para la pancreatitis que contienen anticuerpos anti-receptor il-6 como ingrediente activo.
US6284453B1 (en) 1999-09-29 2001-09-04 Steven Anthony Siano Method for controlling fermentation growth and metabolism
WO2002002793A1 (fr) 2000-07-05 2002-01-10 Japan As Represented By Secretary Of Osaka University Processus de production de glycoproteine
JP4812228B2 (ja) 2000-08-10 2011-11-09 中外製薬株式会社 抗体含有溶液の凝集物生成または白濁抑制方法
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US20040242847A1 (en) 2000-10-20 2004-12-02 Naoshi Fukushima Degraded agonist antibody
PT1356073E (pt) 2000-10-20 2010-02-15 Bioneer As Método de fermentação aperfeiçoado para a produção de produtos genéticos heterólogos em bactérias do ácido láctico
CN1259973C (zh) 2000-10-25 2006-06-21 中外制药株式会社 含有il－6拮抗剂作为有效成分的牛皮癣的预防或治疗剂
WO2002036164A1 (fr) 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Agent abaissant le taux sanguin de vegf contenant un antagoniste de il-6 en tant que principe actif
AU2000279625A1 (en) 2000-10-27 2002-05-15 Chugai Seiyaku Kabushiki Kaisha Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
US7332289B2 (en) 2001-03-09 2008-02-19 Chugai Seiyaku Kabushiki Kaisha Method of purifying protein
WO2002076578A1 (en) 2001-03-27 2002-10-03 Smithkline Beecham Corporation Control of glycoforms in igg
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
AU2002316230A1 (en) 2001-06-13 2002-12-23 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
EP3192528A1 (en) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
JP4432031B2 (ja) 2002-03-22 2010-03-17 ズィナイス オペレーションズ ピーティーワイ．エルティーディー． インターロイキン１３受容体α１（ＩＬ−１３Ｒα１）に対するモノクローナル抗体
JP3822137B2 (ja) 2002-05-20 2006-09-13 中外製薬株式会社 動物細胞培養用培地の添加剤およびそれを用いたタンパク質の製造方法
AU2003262087B2 (en) 2002-09-11 2010-11-11 Chugai Seiyaku Kabushiki Kaisha Protein purification method
AU2003291254A1 (en) 2002-11-05 2004-06-07 Mount Sinai School Of Medicine Of New York University ; Ptpn11 (shp-2) mutations and cancer
DE10255508A1 (de) 2002-11-27 2004-06-17 Forschungszentrum Jülich GmbH Verfahren zur Kultivierung von Zellen zur Produktion von Substanzen
CN100340294C (zh) 2003-02-24 2007-10-03 中外制药株式会社 含有白介素6拮抗剂的脊髓损伤治疗剂
TW200420554A (en) 2003-03-31 2004-10-16 Kyowa Hakko Kogyo Kk A intra-airway administrating preparation
WO2004087756A2 (en) 2003-04-02 2004-10-14 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
DK1623019T4 (en) 2003-05-15 2017-03-27 Wyeth Llc LIMITED GLUCOSE SUPPLY TO ANIMAL CELL CULTURE
US7579157B2 (en) 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
NZ546557A (en) 2003-10-17 2010-01-29 Chugai Pharmaceutical Co Ltd Therapeutic agent for mesothelioma comprising interleukin-6
US8617550B2 (en) 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
US8398980B2 (en) 2004-03-24 2013-03-19 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleuken-6 receptor
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
KR20130101161A (ko) 2005-01-05 2013-09-12 추가이 세이야쿠 가부시키가이샤 세포의 배양 방법 및 그 이용
WO2007043641A1 (ja) 2005-10-14 2007-04-19 Fukuoka University 膵島移植における移植膵島障害抑制剤
BRPI0617664B8 (pt) 2005-10-21 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
AR057941A1 (es) 2005-11-25 2007-12-26 Univ Keio Agentes terapeuticos para el cancer de prostata
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
EP3135298B1 (en) 2006-01-27 2018-06-06 Keio University Therapeutic agents for diseases involving choroidal neovascularization
US20090061466A1 (en) 2006-03-09 2009-03-05 Wolfgang Hoesel Anti-drug antibody assay
CN101495146B (zh) 2006-04-07 2012-10-17 国立大学法人大阪大学 肌肉再生促进剂
WO2008016134A1 (fr) 2006-08-04 2008-02-07 Norihiro Nishimoto PROCÉDÉ POUR PRÉDIRE LE PRONOSTIC DES PATIENTS ATTEINTS DE POLYARTHRITE rhumatoïde
TWI434855B (zh) 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途
JP2010095445A (ja) 2006-12-27 2010-04-30 Tokyo Medical & Dental Univ Ｉｌ−６アンタゴニストを有効成分とする炎症性筋疾患治療剤
TWI438208B (zh) 2007-01-23 2014-05-21 Chugai Pharmaceutical Co Ltd 抑制慢性排斥反應之藥劑
JP5424330B2 (ja) 2007-07-26 2014-02-26 国立大学法人大阪大学 インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
CL2008002885A1 (es) 2007-09-26 2010-07-02 Chugai Pharmaceutical Co Ltd Anticuerpo anti-receptor de interleucina-6 (il-6); y composicion farmaceutica que lo comprende
KR101601986B1 (ko) 2007-10-02 2016-03-17 추가이 세이야쿠 가부시키가이샤 인터류킨 6 수용체 저해제를 유효 성분으로 하는 이식편대숙주병 치료제
MX2010004007A (es) 2007-10-15 2010-06-15 Chugai Pharmaceutical Co Ltd Metodo para la produccion de un anticuerpo.
US8227195B2 (en) * 2007-12-15 2012-07-24 Hoffman-La Roche Inc. Distinguishing assay
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
DE102008005523A1 (de) 2008-01-23 2009-07-30 Robert Bosch Gmbh Kraftstoffinjektor
CA2717614A1 (en) 2008-03-11 2009-09-17 Genentech, Inc. Antibodies with enhanced adcc function
DE102008013899A1 (de) 2008-03-12 2009-09-17 F. Hoffmann-La Roche Ag Verfahren zur Herstellung rekombinanter Proteine bei konstantem Gehalt von pCO2 im Medium
KR101665729B1 (ko) 2008-06-05 2016-10-12 국립연구개발법인 고쿠리츠간켄큐센터 신경침윤 억제제
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
MY161541A (en) 2009-07-31 2017-04-28 Shin Maeda Cancer metastasis inhibitor
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
DK2493922T3 (en) 2009-10-26 2017-04-24 Hoffmann La Roche Process for preparing a glycosylated immunoglobulin
WO2011128096A1 (en) 2010-04-16 2011-10-20 Roche Diagnostics Gmbh Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
DK2578231T3 (da) 2010-05-28 2022-12-12 Chugai Pharmaceutical Co Ltd Antitumor-t-celle-reaktionsforstærker
WO2011149046A1 (ja) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター 膵癌治療剤
EP2576824A2 (en) 2010-06-07 2013-04-10 Roche Diagnostics GmbH Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
CN103476793A (zh) 2010-11-08 2013-12-25 基因技术公司 皮下施用的抗-il-6受体抗体
MY182178A (en) 2011-09-01 2021-01-18 Chugai Pharmaceutical Co Ltd Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration

Also Published As

Publication number Publication date
RU2016101730A3 (zh) 2018-05-15
WO2015000865A1 (en) 2015-01-08
MX363403B (es) 2019-03-22
CA2913687C (en) 2022-12-13
JP2019207246A (ja) 2019-12-05
CN105378480A (zh) 2016-03-02
JP6563910B2 (ja) 2019-08-21
RU2016101730A (ru) 2017-08-09
JP2016530495A (ja) 2016-09-29
US20160313322A1 (en) 2016-10-27
CA2913687A1 (en) 2015-01-08
US10168326B2 (en) 2019-01-01
CN105378480B (zh) 2018-06-12
EP3017303A1 (en) 2016-05-11
JP6761085B2 (ja) 2020-09-23
US10761091B2 (en) 2020-09-01
KR20160029034A (ko) 2016-03-14
BR112015032960A8 (pt) 2019-12-31
MX2015016389A (es) 2016-04-11
BR112015032960B1 (pt) 2021-01-05
EP3017303B1 (en) 2018-01-03
RU2674996C2 (ru) 2018-12-14
KR102248581B1 (ko) 2021-05-06
US20190094216A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
HK1217759A1 (zh) 檢測血清樣品中抗藥物抗體的干擾抑制性免疫測定
HK1221505A1 (zh) 用於檢測光度測定法的前帶效應的方法
HK1222180A1 (zh) 用於生物樣品中的具有提高的性能的 測定
HK1221490A1 (zh) 以生物樣品進行的針對 的具有改進的性能的測定
IL269870B (en) A competitive ligand-binding assay for the detection of neutralizing antibodies
EP2947458A4 (en) PROCESS FOR THE IMMUNOLOGICAL DETERMINATION OF HEMOGLOBIN-A1C IN SAMPLES
HK1206398A1 (zh) 用於在親和生物測定中檢測分析物的裝置
SG11201402709WA (en) Method and device for assaying an antigen present on erythrocytes or an antibody binding to an antigen present on erythrocytes
HK1223112A1 (zh) 抗- -α/ 雙靶向抗體及其應用
HK1203621A1 (zh) 分析物測試儀數字樣品檢測
EP2952896A4 (en) PROCESS FOR REDUCING INCORRECT NEGATIVES IN AN IMMUNOASSAY FOR DETERMINING SPECIMENS DERIVED FROM BIOMEMBRANES
EP2950099A4 (en) PROCESS FOR PREPARING A SAMPLE FOR THE DETECTION OF HBS ANTIGEN AND USE THEREOF
GB2515299B (en) Methods and apparatus for determining analyte in a sample
EP2962105A4 (en) METHODS AND REAGENTS FOR DETERMINING ISOMERIC ANALYTES
GB201300869D0 (en) Improvements in or relating to sample analysis
HK1221769A1 (zh) 用於結合親和力的檢測的裝置
EP2902782A4 (en) IMMUNOLOGICAL DETECTION METHOD AND REAGENT FOR IMMUNOLOGICAL DETECTION
SG11201406160QA (en) Method for producing reagent for antibody detection and use thereof
EP3064943A4 (en) Antigen detection method using sandwich immunoassay method
HK1222597A1 (zh) 用於檢測液體樣本中的分析物的檢測裝置
EP2970853A4 (en) SAMPLING AND SAMPLE ANALYSIS
GB201303168D0 (en) Immunoassay for detecting kratom, Its constituents and their use
EP2833141A4 (en) IMMUNOLOGICAL ANALYSIS METHOD AND REAGENT
HK1211083A1 (zh) 用於測量非稀釋類型免疫層析法試劑中的樣品的添加劑
HK1220255A1 (zh) 檢測分子的方法